Hepatocyte growth factor as a prognostic marker in heart failure: Promise and challenges

Cardiology (Switzerland)

Volumn 121, Issue 4, 2012, Pages 237-239

  Fountoulaki, K ^a,b   Parissis, J ^b  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; SCATTER FACTOR;

CARDIOVASCULAR MORTALITY; CHAGAS DISEASE; CONGESTIVE CARDIOMYOPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; NOTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; BLOOD; FEMALE; MALE;

BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; CHAGAS DISEASE; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE;

EID: 84860597061     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000338158     Document Type: Note

References (27)

1. Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med 1998;339:321-328. (Pubitemid 28366422)
2. Pascual-Figal DA, Domingo M, Casas T, Gich I, Ordoñez-Llanos J, Martínez P, Cinca J, Valdés M, Januzzi JL, Bayes-Genis A: Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. Eur Heart J 2008;29:1011-1018. (Pubitemid 351844674)
3. Nagarajan V, Tang WH: Biomarkers in advanced heart failure: diagnostic and therapeutic insights. Congest Heart Fail 2011;17:169-174.
4. van Kimmenade RR, Januzzi JL Jr: Emerging biomarkers in heart failure. Clin Chem 2012;58:127-138.
5. Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35:569-582. (Pubitemid 30167013)
6. Sutton MG, Sharpe N: Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000;101:2981-2988. (Pubitemid 30415891)
7. Abbate A, Biondi-Zoccai GG, Baldi A: Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling. J Cell Physiol 2002;193:145-153.
8. Nian M, Lee P, Khaper N, Liu P: Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004;94:1543-1553. (Pubitemid 38856961)
9. Spinale FG: Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007;87:1285-1342.
10. Wang Y, Moreira MCV, Khan A, Heringer-Walther S, Schultheiss H-P, Wessel N, Siems W-E, Walther T: Prognostic significance of circulating levels of hepatocyte growth factor in patients with Chagas' disease and idiopathic dilated cardiomyopathy. Cardiology 2012;121:240-246.
11. Lamblin N, Susen S, Dagorn J, Mouquet F, Jude B, Van Belle E, Bauters C, de Groote P: Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure. Am Heart J 2005;150:137-143. (Pubitemid 41097441)
12. Rychli K, Richter B, Hohensinner PJ, Kariem Mahdy A, Neuhold S, Zorn G, Berger R, Mörtl D, Huber K, Pacher R, Wojta J, Niessner A, Hülsmann M: Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure. Heart 2011;97:1158-1163.
13. Nakamura T, Mizuno S: The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B Phys Biol Sci 2010;86:588-610.
14. Boros P, Miller CM: Hepatocyte growth factor: a multifunctional cytokine. Lancet 1995;345:293-295.
15. Matsumoto K, Nakamura T: Emerging multipotent aspects of hepatocyte growth factor. J Biochem 1996;119:591-600. (Pubitemid 26131762)
16. Ueda H, Nakamura T, Matsumoto K, Sawa Y, Matsuda H, Nakamura T: A potential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats. Cardiovasc Res 2001;51:41-50. (Pubitemid 32523053)
17. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S: Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 1997;95:2552-2558. (Pubitemid 27233121)
18. Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H, Nakamura T: Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 2000;106:1511-1519. (Pubitemid 32038589)
19. Zhu Y, Hojo Y, Ikeda U, Shimada K: Production of hepatocyte growth factor during acute myocardial infarction. Heart 2000;83:450-455. (Pubitemid 30316765)
20. Lamblin N, Bauters A, Fertin M, de Groote P, Pinet F, Bauters C: Circulating levels of hepatocyte growth factor and left ventricular remodelling after acute myocardial infarction (from the REVE-2 study). Eur J Heart Fail 2011;13:1314-1322.
21. Jayasankar V, Woo YJ, Bish LT, Pirolli TJ, Chatterjee S, Berry MF, Burdick J, Gardner TJ, Sweeney HL: Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure. Circulation 2003;108(suppl 1):II230-236. (Pubitemid 37099960)
22. Li Y, Takemura G, Kosai K, Yuge K, Nagano S, Esaki M, Goto K, Takahashi T, Hayakawa K, Koda M, Kawase Y, Maruyama R, Okada H, Minatoguchi S, Mizuguchi H, Fujiwara T, Fujiwara H: Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. Circulation 2003;107:2499-2506. (Pubitemid 36605235)
23. Ueno S, Ikeda U, Hojo Y, Arakawa H, Nonaka M, Yamamoto K, Shimada K: Serum hepatocyte growth factor levels are increased in patients with congestive heart failure. J Card Fail 2001;7:329-334. (Pubitemid 34008164)
24. Nakamura Y, Morishita R, Nakamura S, Aoki M, Moriguchi A, Matsumoto K, Nakamura T, Higaki J, Ogihara T: A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension 1996;28:409-413. (Pubitemid 26296043)
25. Nakamura S, Morishita R, Moriguchi A, Yo Y, Nakamura Y, Hayashi S, Matsumoto K, Matsumoto K, Nakamura T, Higaki J, Ogihara T: Hepatocyte growth factor as a potential index of complication in diabetes mellitus. J Hypertens 1998;16:2019-2026. (Pubitemid 29002383)
26. Taniguchi T, Toi M, Tominaga T: Rapid induction of hepatocyte growth factor by heparin. Lancet 1994;344:470. (Pubitemid 24248256)
27. Hu ZP, Wang BN, Qian HY, Zhou Q, Wei W, Wang Y: Fixed-dose telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in decreasing serum hepatocyte growth factor and improving endothelial dysfunction in hypertensive patients. Int Heart J 2010;51:252-258.